CATX Perspective Therapeutics, Inc.

XASE 2.29 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

CATX $2.29 —
Key stats
$2.29
52-Week Range
$1.96 – $6.16
YTD
-17.89%
IV Rank (30D)
34.33
Straddle Price
$0.65
P/C Vol Ratio
2.00
Market Cap
$0.3B
Open
$2.25
Day Range
$2.24 – $2.33
Volume
296,048
Prev Close
$2.30
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.15%
Beta vs SPY1.00
Cost of Equity (CAPM)10.67% (VRP-adj)
WACC10.38%
Volatility Risk Premium+288.2pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)-10.0%
DCF Horizon10 years explicit + fade
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-35.9%
Book / Price185.4% — banking bias active (P/B is primary)
Gross Margin (TTM)100.0%
FCF Margin (TTM)-19627.5%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
SMA 50$2.83 (Market Anchor value)
SMA 20 / Bollinger Mid$2.47
Bollinger Width / SMA201228.9% (drives anchor stability)
Net Debt$-0.1B
Market Cap$0B
Peers used for multiples: ABT, NVS, PFE (SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
58%
20-Day Fair Value
≈ by Nov 20, 2026
$2.31
α +0.1% rank 99%
conviction
8%
40-Day Fair Value
≈ by Dec 21, 2026
$2.37
α +2.9% rank 99%
conviction
82%
60-Day Fair Value
≈ by Jan 19, 2027
$2.34
α +1.7% rank 99%
conviction
58%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 39.6× · 3 peers
Peer EV/EBITDA n/a 0% median 19.0× · 3 peers
Peer P/B $14.80 20% median 3.5× · 3 peers
Peer P/S $0.03 20% median 3.8× · 3 peers
Market Anchor (SMA50) $2.83 61% stability 61% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-10-22 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XASE
Market Cap
$0.3B
Employees
166
List Date
2003-12-29
CIK
0000728387
Next Earnings
2026-11-09 (Pre-Market)
EPS Forecast
($0.24) (7 est.)
Headquarters
Seattle, WA
Homepage
https://www.perspectivetherapeutics.com

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'23'24'25'26Avg
Jan--101.87%7.25%35.84%48.32%
Feb-3.95%10.67%-15.76%6.72%-0.58%
Mar74.84%25.42%-13.41%-22.06%16.20%
Apr-9.80%31.25%25.00%-11.76%8.67%
May-13.71%-18.82%4.05%2.34%-6.54%
Jun26.49%-27.23%43.93%-6.83%9.09%
Jul-17.26%21.43%17.07%-16.50%1.18%
Aug-30.17%17.91%-8.70%4.98%-4.00%
Sep-32.42%-5.85%3.31%-11.29%-11.56%
Oct-4.07%-6.49%-20.41%-15.26%*-11.56%
Nov-3.04%-64.02%-9.62%---25.56%
Dec54.62%-23.13%25.57%--19.02%
Total-7.16%-24.26%46.07%-37.36%-5.68%
* Only 4 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $2.46
SMA 50: $2.81
SMA 200: $3.58
Current: $2.31
EMA 12: $2.36
EMA 26: $2.52
MACD: -0.1536 | Signal: -0.0038
BEARISH
ADX (14): 20.97
WEAK TREND
+DI: 16.98
−DI: 27.78

Momentum Oscillators

RSI (14): 41.10
NEUTRAL
Stoch %K: 22.64
Stoch %D: 16.67
Williams %R: -76.87

Volume & Volatility

BB Upper: $2.85
BB Lower: $2.08
NEUTRAL
OBV: 78,114,623
Vol SMA 20: 1,664,023
Vol ROC: -91.09%
ATR: $0.17
True Range: $0.09
HV 20: 83.5%
HV 30: 83.5%
HV 60: 71.2%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis

LLM Stock Analysis Report: CATX

Executive Summary

Overall Assessment: NEUTRAL (Confidence Level: 6/10)

Key Drivers: Strong positive sentiment from recent news headlines, moderate volatility, and a beta close to the market average.

Primary Risks: Oversold technical conditions, potential for mean reversion, and moderate institutional interest.

Investment Thesis: CATX presents a moderately attractive opportunity with a balance of risk and reward. The stock is oversold technically, which could lead to a rebound or correction. News sentiment remains positive, but the market is pricing in a modest move by expiration.

Recent News Sentiment Impact: Positive news headlines have driven the recent price action, with all five articles showcasing promising developments for Perspective Therapeutics (CATX). This has contributed to the overall bullish tone and may continue to influence the stock's performance.

Technical Analysis

Trend Direction: Short-term: Bearish (1-4 weeks), Medium-term: Neutral (1-3 months), Long-term: Bullish (3-12 months)

Support/Resistance Levels: The 20-SMA ($3.08) serves as a key support level, while the upper Bollinger Band ($3.48) represents resistance.

Momentum Signals:

  • RSI Interpretation: Oversold (<30), with a reading of 34.27.
  • MACD Signal: Bearish (below signal line).
  • Bollinger Bands Position: Oversold, indicating a potential rebound or correction.

Volume Analysis: Moderate institutional interest, with a volume rate of change of -22.34%. On-Balance Volume (OBV) suggests a bearish momentum.

News & Sentiment Analysis

Recent Headlines Summary: Positive news headlines from Perspective Therapeutics, focusing on clinical trial updates and market growth prospects.

Sentiment Assessment: Aggregate sentiment is positive (4/5), reflecting the overall tone of recent news articles.

Catalyst Identification: Upcoming investor conferences and earnings reports may provide additional catalysts for the stock's price action.

Market Narrative: The market is pricing in a modest move by expiration, with options activity suggesting a potential bounce or correction.

Risk & Volatility Assessment

Beta Interpretation: Moderate risk relative to the market (beta = 0.91).

Volatility Regime: Current volatility levels are relatively low compared to historical averages.

Options Market Signals:

  • IV Rank: Low (16.4%), indicating historically low volatility.
  • Put/Call Volume Ratio: Bullish sentiment (0.17).
  • Market Expectation: Options market pricing $0.45 move by expiration, which is relatively modest.

Market Context & Positioning

Sector Performance: The healthcare sector has been trending upwards, with CATX generally following the market's direction.

Institutional Activity: Moderate institutional interest, reflected in volume patterns and options activity.

Correlation Analysis: Stock moves relatively closely to the market (R-squared = 0.11), indicating a moderate correlation.

Relative Valuation: Position within a trading range, with potential for mean reversion or correction.

Key Levels & Action Items

Critical Price Levels:

  • Support: $2.67 (lower Bollinger Band)
  • Resistance: $3.48 (upper Bollinger Band)

Breakout/Breakdown Levels:

  • Breakout above the 20-SMA ($3.08) could trigger a bullish move.
  • Breakdown below $2.50 could lead to further declines.

Time-Sensitive Catalysts: Upcoming investor conferences and earnings reports may provide additional catalysts for the stock's price action.

Risk Management: Consider stop-loss levels around $2.40 (20% below current price) and position sizing considerations based on risk tolerance and market conditions.

Generated
News
All CATX news →
Showing 1–10 of 50
Page 1 of 5
Earnings History
11 of 11 under expected move
Avg Expected Move
69.13%
Avg Actual Move
3.24%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-08-12 Pre-Market 81.53% 0.58% 0.01x Within
2024-11-12 Pre-Market 19.16% 3.79% 0.20x Within
2025-01-13 Pre-Market 214.29% 2.86% 0.01x Within
2025-03-26 Pre-Market 71.67% 8.10% 0.11x Within
2025-05-12 Pre-Market 100.00% 6.81% 0.07x Within
2025-08-13 After-Close 44.62% 2.36% 0.05x Within
2025-10-20 After-Close 93.26% 2.51% 0.03x Within
2026-01-09 Pre-Market 16.90% 1.07% 0.06x Within
2026-03-16 Pre-Market 14.50% 4.40% 0.30x Within
2026-05-11 Pre-Market 67.82% 3.19% 0.05x Within
2026-08-10 Pre-Market 36.67% 0.00% 0.00x Within

Earnings calendar: this week’s reports with expected vs actual moves →

CATX Options Activity & IV Rank

CATX IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 143.8%
7-DTE IV: —
Expected Move: $0.65
7-DTE Move: $0.65
Days to Exp: 29 (2026-11-20)

Options Flow

Call Volume: 2
Put Volume: 4
P/C Volume: 2.0
BEARISH
Call OI: 659
Put OI: 4
P/C OI: 0.006
Total OI: 663

ATM Options Pricing

ATM Call: $0.23
ATM Put: $0.42
Call %: 9.8%
Put %: 18.6%

Chain Summary

Chain Volume: 55
Chain OI: 11,312
Last Updated: 10/22/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 48th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
48%
vs own history
GEX tilt
+0.54
OI-weighted, today
Vanna tilt
+0.50
δ-sensitivity to IV
Charm tilt
-0.68
δ-decay vs time
Vanna tilt +0.50: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.68: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 3 ATM contracts, 2k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
No data
30 DTE / 10d —
— pts EXTREME
ATM 335.9% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)34.3MediumOct 22
Straddle Price (30 DTE)$0.65Oct 22
Beta Analysis

Risk Metrics

Beta: 1.5520
Alpha: -3.66%
Correlation: 0.1915
R-Squared: 3.7%
Stock Volatility: 103.2%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own CATX
3 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$16.7M
0.01%
#1237 of 3716+21.4%13F
Citadel Hedge fund
Ken Griffin
$13.0M
0.01%
#1399 of 6285+6.7%13F
Renaissance Technologies Hedge fund
Jim Simons
$202K
0.00%
#2879 of 3138new13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

CATX Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 81,487,000 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

132 filers90,979,672 shares$307.72M value111.65% of float
# Filer Shares Value % of Total % of Float Period
1 BlackRock, Inc. Custodian 9,494,152 $32.38M 10.52% 11.65% 2026-06-30
2 TCG Crossover Management, LLC 7,915,567 $26.99M 8.77% 9.71% 2026-06-30
3 Commodore Capital LP 6,336,782 $21.61M 7.02% 7.78% 2026-06-30
4 Avidity Partners Management LP 6,299,999 $21.48M 6.98% 7.73% 2026-06-30
5 State Street Corp 6,051,771 $20.64M 6.71% 7.43% 2026-06-30
6 Millennium Management LLC Custodian 4,911,855 $16.75M 5.44% 6.03% 2026-06-30
7 Vanguard Capital Management LLC 4,436,572 $15.13M 4.92% 5.44% 2026-06-30
8 Affinity Asset Advisors, LLC 4,214,582 $14.37M 4.67% 5.17% 2026-06-30
9 Citadel Advisors LLC Custodian 3,805,739 $12.98M 4.22% 4.67% 2026-06-30
10 Spruce Street Capital LP 3,693,931 $12.60M 4.09% 4.53% 2026-06-30
11 Balyasny Asset Management L.P. 3,320,224 $11.32M 3.68% 4.07% 2026-06-30
12 Vanguard Group Inc Custodian 3,490,658 $9.60M 3.12% 4.28% 2025-12-31
13 Geode Capital Management, LLC Custodian 2,458,673 $8.39M 2.73% 3.02% 2026-06-30
14 Nantahala Capital Management, LLC 2,325,450 $7.93M 2.58% 2.85% 2026-06-30
15 Morgan Stanley Custodian 1,912,550 $6.52M 2.12% 2.35% 2026-06-30
16 Goldman Sachs Group Inc Custodian 1,733,078 $5.91M 1.92% 2.13% 2026-06-30
17 Nicholson Wealth Management Group, LLC 1,619,993 $5.52M 1.80% 1.99% 2026-06-30
18 Two Sigma Investments, LP Custodian 1,556,451 $5.31M 1.72% 1.91% 2026-06-30
19 ADAR1 Capital Management, LLC 1,210,117 $4.13M 1.34% 1.49% 2026-06-30
20 Vanguard Portfolio Management LLC 1,087,767 $3.71M 1.21% 1.33% 2026-06-30
21 Dimensional Fund Advisors LP Custodian 1,074,071 $3.66M 1.19% 1.32% 2026-06-30
22 Yu Fan 1,055,409 $3.60M 1.17% 1.30% 2026-06-30
23 Hills Bank & Trust Co 872,200 $2.97M 0.97% 1.07% 2026-06-30
24 Northern Trust Corp Custodian 791,774 $2.70M 0.88% 0.97% 2026-06-30
25 Charles Schwab Investment Management, Inc. 773,262 $2.64M 0.86% 0.95% 2026-06-30
3 filers$452.17K notional
# Filer Notional Value % of Total Period
1 GROUP ONE TRADING LLC Custodian $281.32K 62.22% 2026-06-30
2 Susquehanna International Group, LLP Custodian $158.91K 35.14% 2026-06-30
3 Simplex Trading, LLC Custodian $11.94K 2.64% 2026-06-30
1 filers$1.02K notional
# Filer Notional Value % of Total Period
1 GROUP ONE TRADING LLC Custodian $1.02K 100.00% 2026-06-30

CATX Insider Trading (Form 4)

Latest: 2026-09-08
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-08 Lantheus Holdings, Inc. 10%+ Owner Sell (S) −495,864 $3.13 -$1.55M EDGAR
2026-09-04 Lantheus Alpha Therapy, LLC 10%+ Owner Sell (S) −84,258 $3.11 -$262.4K EDGAR
2026-09-04 Lantheus Alpha Therapy, LLC 10%+ Owner Sell (S) −113,914 $3.14 -$357.2K EDGAR
2026-09-03 Lantheus Holdings, Inc. 10%+ Owner Sell (S) −35,769 $3.12 -$111.6K EDGAR
2026-09-02 Lantheus Holdings, Inc. 10%+ Owner Sell (S) −78,145 $3.14 -$245.6K EDGAR
2026-03-04 Frank Morich Director Grant (A) +50,000 opt — EDGAR
2026-03-04 Jonathan Robert Hunt Chief Accounting Officer Grant (A) +90,000 opt — EDGAR
2026-03-04 Lori A Woods Director Grant (A) +50,000 opt — EDGAR
2026-03-04 Markus Puhlmann Chief Medical Officer Grant (A) +150,000 opt — EDGAR
2026-03-04 Johan M. Spoor Chief Executive Officer Grant (A) +735,000 opt — EDGAR
2026-03-04 Heidi Henson Director Grant (A) +50,000 opt — EDGAR
2026-03-04 Robert F Williamson III Director Grant (A) +50,000 opt — EDGAR
2026-03-04 Maria E Martinez Director Grant (A) +50,000 opt — EDGAR
2025-11-17 Jonathan Robert Hunt Chief Accounting Officer Buy (P) +11,000 $2.03 $22.3K EDGAR
2025-11-14 Robert F Williamson III Director Buy (P) +9,498 $2.10 $19.9K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

CATX Insider Holdings

9 insiders · @ $2.31
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Lantheus Alpha Therapy, LLC 10%+ Owner 11,599,194 $26.74M -$619.6K 2 2026-09-04
2 Lantheus Holdings, Inc. 10%+ Owner 11,440,513 $26.37M $112.91M 4 2026-09-08
3 Lori A Woods Director 188,267 $434.0K $200.0K 11 2026-03-04
4 Markus Puhlmann Chief Medical Officer 137,542 $317.0K $328.6K 6 2026-03-04
5 Robert F Williamson III Director 118,846 $273.9K $493.7K 16 2026-03-04
6 Johan M. Spoor Chief Executive Officer 64,783 $149.3K $307.7K 9 2026-03-04
7 Jonathan Robert Hunt Chief Accounting Officer 59,800 $137.8K $156.3K 9 2026-03-04
8 Juan Graham Chief Financial Officer 35,354 $81.5K $74.9K 2 2025-04-01
9 Heidi Henson Director 25,975 $59.9K $100.0K 6 2026-03-04
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

CATX Board & Officers

As of SEC filings through Sep 8, 2026

Directors 6

Officers 4

Changes in the last 10 years (33)
Sep 8, 2026Lantheus Holdings, Inc. reported in an SEC filing no longer being a 10% owner
Sep 8, 2026Lantheus Alpha Therapy, LLC reported in an SEC filing no longer being a 10% owner
Sep 4, 2025Joel Sendek became Chief Financial Officer
Sep 3, 2025Maria E Martinez became a director
Sep 2, 2025The company announced the departure of Juan Graham as Chief Financial Officer in an SEC filing
Mar 5, 2025Jonathan Robert Hunt listed as Chief Accounting Officer (previously Chief Financial Officer) in SEC filings
Jan 6, 2025Juan Graham became Chief Financial Officer
Aug 16, 2024The company announced the departure of Mark John Austin as VP Finance/Prin Fin&Acct Offic in an SEC filing
Jan 22, 2024Lantheus Holdings, Inc. became a 10% owner
Jan 22, 2024Lantheus Alpha Therapy, LLC became a 10% owner
Jun 1, 2023Heidi Henson became a director
May 9, 2023The company announced the departure of Michael W McCormick from the board in an SEC filing
Feb 3, 2023Robert F Williamson III became a director
Feb 3, 2023Markus Puhlmann became Chief Medical Officer
Feb 3, 2023Johan M. Spoor became a director
Feb 3, 2023Johan M. Spoor became CEO
Feb 3, 2023Frank Morich became a director
Feb 1, 2023The company announced the departure of Lori A Woods as CEO in an SEC filing
Jan 31, 2023The company announced the departure of Philip J Vitale from the board in an SEC filing
Jan 31, 2023The company announced the departure of Alan Hoffmann from the board in an SEC filing
Not reported recently (6)
  • Jennifer Streeter · Last reported as COO & VP of HR in an SEC filing dated Jun 14, 2023
  • William Cavanagh · Last reported as Chief R&D Officer in an SEC filing dated Aug 1, 2022
  • Michael Krachon · Last reported as EVP of Sales & Marketing in an SEC filing dated Oct 28, 2020
  • Krista Cline · Last reported as Dir. of Operations, Secretary in an SEC filing dated Jun 25, 2020
  • Thomas C Lavoy · Last reported as a director in an SEC filing dated Mar 2, 2018
  • Matthew Branson · Last reported as Principal Fin & Acct Officer in an SEC filing dated Jul 6, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

CATX Proposed Insider Sales (Form 144)

Latest: 2024-09-12
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2024-09-12 Mark Austin affiliate 2,500 $39.5K 2024-09-12 Global Shares Financial Services… — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
31 ETFs hold CATX
25 shown · $30.34M total exposure · 0.01% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $9.1M — 2026-09-30
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.01% $6.0M $75.1B 2026-10-20
3 VXF Vanguard Extended Market ETF Vanguard 0.00% $2.7M — 2026-09-30
4 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.02% $2.2M $13.7B 2026-10-20
5 VTWO Vanguard Russell 2000 ETF Vanguard 0.01% $1.7M — 2026-09-30
6 SCHA Schwab U.S. Small-Cap ETF Nport 0.01% $1.6M — 2026-05-31
7 IBB iShares Biotechnology ETF iShares (BlackRock) 0.01% $1.6M $11.0B 2026-10-20
8 DFAS Dimensional US Small Cap ETF Dimensional 0.00% $1.4M — 2026-10-20
9 VHT Vanguard Health Care ETF Vanguard 0.00% $773,149 — 2026-09-30
10 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.06% $717,600 $1.2B 2026-10-20
11 DFMC Dimensional US Micro Cap ETF Dimensional 0.01% $619,390 — 2026-10-20
12 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.01% $452,592 $6.6B 2026-10-20
13 AVSC Avantis U.S. Small Cap Equity ETF Avantis 0.01% $318,417 $3.1B 2026-10-20
14 VTWV Vanguard Russell 2000 Value ETF Vanguard 0.02% $261,214 — 2026-09-30
15 SCHB Schwab U.S. Broad Market ETF Nport 0.00% $250,277 — 2026-05-31
16 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.00% $220,409 — 2026-10-20
17 DXUV Dimensional US Vector Equity ETF Dimensional 0.00% $126,212 — 2026-10-20
18 RSSL Global X Russell 2000 ETF Global X 0.01% $115,941 — 2026-10-21
19 DFAU Dimensional US Core Equity Market ETF Dimensional 0.00% $74,127 $13.1B 2026-10-20
20 IWV iShares Russell 3000 ETF iShares (BlackRock) 0.00% $35,123 $20.6B 2026-10-20
21 DCOR Dimensional US Core Equity 1 ETF Dimensional 0.00% $29,948 — 2026-10-20
22 RFLR Innovator U.S. Small Cap Managed Floor ETF Innovator 0.03% $28,863 $94.3M 2026-10-21
23 VTHR Vanguard Russell 3000 ETF Vanguard 0.00% $24,591 — 2026-09-30
24 ITWO ProShares Russell 2000 High Income ETF ProShares 0.01% $13,708 — 2026-10-21
25 URTY ProShares UltraPro Russell2000 ProShares 0.00% $10,677 — 2026-10-21
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-1.40
TTM Revenue
$618.00K
TTM Net Income
$-111.13M
TTM Op. Cash Flow
$-92.37M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q1 '262026-03-31$76.00K$-26.19M$-0.25$-31.47M
Q4 '252025-12-31$43.00K$-37.49M$-0.51$-24.66M
Q3 '252025-09-30$209.00K$-25.97M$-0.35$-16.29M
Q2 '252025-06-30$290.00K$-21.48M$-0.29$-19.95M
Q1 '252025-03-31$342.00K$-18.18M$-0.25$-21.58M
Q4 '242024-12-31$234.00K$-40.17M$-0.61$-26.61M
Q3 '242024-09-30$369.00K$-15.12M$-0.21$3.37M
Q2 '242024-06-30$526.00K$-11.70M$-0.18$-8.90M
Q1 '242024-03-31$325.00K$-12.28M$-0.25$13.85M
Q4 '232023-12-31$337.00K$-24.68M$-0.91$-9.01M
Q3 '232023-09-30$276.00K$-10.36M$-0.37$-10.11M
Q2 '232023-06-30$588.00K$-11.11M$-0.40$-8.07M
Q1 2026 • period ending 2026-03-31 • filed 2026-05-11
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.54
P/S
303.93
EV/EBITDA
—
EV/Sales
219.11
ROE
-32.0%
ROA
-27.1%
Div Yield
0.00%
FCF Yield
-49.18%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$187.83M
as of 2026-10-22
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
16.57M
SI % of Float
17.43%
Days to Cover
5.52
Short Vol Ratio
66.1%
Free Float
95.07M
Float %
83.3%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-09-04